GLP-1 Receptor Agonists and SGLT2 Inhibitors Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are recommended by several international diabetes management guidelines for treating diabetes patients with cardiovascular disease or kidney disease. These classes of drugs provide better glycemic control and reduce non-fatal myocardial infarction, kidney failure, and mortality. Semaglutide Semaglutide is the most recently approved GLP-1 RA to improve glycemic control and lose weight in diabetes and obese patients.
Unlike other GLP-1RAs, semaglutide can be administered subcutaneously or orally. Several clinical trials have been conducted to determine the safety and efficacy of semaglutide. While semaglutide is not associated with major safety concerns, it is found to increase cholelithiasis risk and cause mild and transient…
